Skip to main content
Download PDF

Interferon-gamma release assay for screening of tuberculosis infection in children

BMC Infectious Diseases volume 23, Article number: 873 (2023) Cite this article

Abstract

Background

Interferon-gamma release assay (IGRA) is the main tool for the diagnosis of latent tuberculosis (TB) infection (LTBI). However, the indeterminate results were more frequent in children, and the underlying reasons were largely speculative. We aimed to compare QuantiFERON-TB Gold In-Tube (QFT-GIT) with X.DOT-TB (XDOT) for diagnosing LTBI, and to identify the risk factors associated with indeterminate results in children.

Methods

A retrospective study for children<18 years old, at risk for LTBI or progression to TB disease, received either QFT-GIT or X.DOT-TB tests was performed at Beijing Children’s Hospital from August 2019 to August 2022.

Results

A total of 33,662 children were recruited, including 15,129 (44.9%) tested with X.DOT-TB and 18,533 (55.1%) with QFT-GIT. Proportion of positive and indeterminate results in children with respiratory disease was significantly higher than did that with other diseases, respectively (P < 0.001). The indeterminate rate of X.DOT-TB and QFT-GIT results decreased with increasing age (P < 0.001). Proportion of QFT-GIT indeterminate results was higher than that of X.DOT-TB across age groups. Male, age and disease classification all presented a statistically significant association with indeterminate IGRA results.

Conclusions

The positive rates of X.DOT-TB and QFT-GIT in children were 3.1% and 1.8%, respectively. The X.DOT-TB assay performed better than QFT-GIT in children, and male, age and underlying diseases were associated with an increased risk of indeterminate IGRA results.

Peer Review reports

Introduction

Tuberculosis (TB) remains a serious threat to public health worldwide. Globally, approximately 10.6 million incident cases were in 2021, including approximately 1.2 million TB cases in children [1]. However, only 10% individuals infected with Mycobacterium tuberculosis (MTB) develop clinically active TB disease, and 90% are asymptomatic and remain in the latent phase, constituting a large reservoir of individuals with latent TB infection (LTBI) [2]. Compared to adults, children with LTBI progress more frequently to active TB [3], and the risk rises as high as 50% for children under one year of age, 6–24% between one and five years and 6–12% in adolescents annually [4]. Therefore, early identification and treatment of LTBI is essential to limit the devastating consequences of TB in children.

Immuno-diagnostic tests are the main tools for the diagnosis of LTBI in clinical setting [1, 2]. Though interferon-gamma release assay (IGRA), based on the host immune response against MTB specific antigens, exhibited higher specificity than TST, which had cross-reactions with BCG vaccination [5]. The indeterminate IGRA results have been shown more frequent in children than adults [3], but the underlying reasons are largely speculative. In our hospital, two commercial kits of IGRAs were used clinically, including QuantiFERON-TB Gold In-Tube (QFT-GIT) (QIAGEN, Germany), which measures the concentration of IFN-γ via an Enzyme-linked Immunosorbent Assay (ELISA), and X.DOT-TB (Signature Biotechnology, China), which measures the frequencies of IFN-γ-secreting cells via Enzyme-linked Immunospot Assay (ELISPOT) [6]. Therefore, the aim of this study was to compare QFT-GIT with X.DOT-TB for diagnosing LTBI, and to identify the risk factors associated with indeterminate results in children.

Methods

Study design and population

We performed a retrospective study for all children<18 years old, at risk for LTBI or progression to TB disease, received either QFT-GIT or X.DOT-TB tests at Beijing Children’s Hospital, the largest children’s hospital of tertiary facility in China, from August 2019 to August 2022. For the inpatient/outpatient children with IGRA results, we extracted information from their medical records home pages, including medical department and characteristics of the patient (primary diagnosis name, clinically diagnosis name, gender, and age).

Disease classification

The children were classified according to the clinical diagnosis of diseases. Respiratory diseases mainly include pneumonia, bronchitis, asthma and other related diseases; central nervous system diseases mainly include encephalitis and meningitis; digestive diseases include vomiting, diarrhea, and abdominal pain; urinary diseases mainly include nephrotic syndrome, acute glomerulonephritis, chronic renal failure, IgA nephropathy; hematological/tumor diseases mainly include leukemia, lymphoma, aplastic anemia; rheumatic immune system diseases mainly include henoch-schonlein purpura, systemic lupus erythematosus, juvenile idiopathic arthritis, dermatomyositis, connective tissue disease; cardiovascular system mainly include myocardial damage, vasculitis, vascular malformation, other mainly include fever, spasm, arthralgia.

X.DOT-TB

PHA was utilized as the positive control, AIM-V as nil control, and ESAT-6 and CFP-10 as specific antigens in X.DOT-TB test. Following X.DOT-TB manufacturer’s instructions, 5 ml of peripheral venous blood obtained from subjects was into heparin lithium-anticoagulant tubes. Peripheral blood mononuclear cells (PBMCs) within 4 h of collection were seeded (2.5 × 106 cell/ml) on a plate precoated with antibody against IFN-γ. Plates were incubated for 20–22 h at 37◦C in 5% carbon dioxide. After incubation, a conjugate against the antibody and enzyme-substrate was generated. Spot-forming cells (SFCs) were counted with an automated ELISpot reader (AID-ispot, Strassberg, Germany). The result was interpreted in supplementary Table 1.

QuantiFERON-TB gold in tube

According to the manufacturer’s instructions, 1 mL of whole blood was collected into each of the three separate test tubes, including a nil tube, a positive tube with mitogen, and a TB antigen tube (containing ESAT-6, CFP-10 and TB7.7), followed by incubation for 16-24 h at 37 °C. The tubes were centrifuged and supernatants were collected to assess the concentration of IFN‐γ (IU/mL) via ELISA. The result was interpreted in supplementary Table 2.

Statistical analysis

Categorical variables were presented as percentages, while continuous variables were presented as means and standard deviations. P-values < 0.05 were considered statistically significant. Multivariable models were built using “Enter” logistic regression procedures. Data analyses were conducted using SPSS version 23.0.

Results

Characteristics of study population

A total of 33,662 children screening for LTBI were recruited, including 15,129 (44.9%) tested with X.DOT-TB and 18,533 (55.1%) with QFT-GIT, and 56.1% were male. The mean age was 7.2 years; 33.8% and 33.6% of the patients were aged 5 to 9 and 0 to 4 years, respectively. Children with rheumatic immune (20.5%) and respiratory diseases (17.6%) were more frequently to be screened for LTBI (Table 1). Except for children with respiratory diseases, the number of children with other diseases in 2019 to 2020 year was all lower than that in the other two years, but there was no significant difference (Fig. 1). Besides, for X.DOT-TB assay, larger number of children under 5 years old with respiratory disease and children aged 5 to 17 years with rheumatic immune disease were screened for LTBI. For QFT-GIT, children under 5 years old with hematological and neoplastic disease, and children aged 5 to 17 years with rheumatic immune and other disease were more common to be tested (Fig. 2).

Table 1 Baseline characteristics of the study population
Full size table
Fig. 1
figure 1

Trends of children with various diseases, 2019 to 2022

Full size image
Fig. 2
figure 2

Distribution of various disease among age groups (A: children screened by X.DOT-TB; B: children screened by QFT-GIT)

Full size image

Results of X.DOT-TB and QFT-GIT assay

Of the 15,129 children tested by X.DOT-TB (Table 2), 472 (3.1%) were positive and 626 (4.1%) were indeterminate. The proportion of positive results in children between 10 and 14 years old (38.8%) was significantly greater than that in other age groups (P < 0.001). The indeterminate rate of X.DOT-TB results decreased with increasing age (P < 0.001). Concerning disease types, the proportion of positive and indeterminate result in children with respiratory disease was significantly higher than did that with other diseases (P < 0.001).

Table 2 X.DOT-TB and QFT-GIT Results
Full size table

Of the 18,533 children tested by QFT-GIT (Table 2), 341 (1.8%) were positive and 2420 (13.1%) were indeterminate. The proportion of positive results in children between 10 and 14 years old (42.5%) was significantly greater than that in other age groups (P < 0.001). The indeterminate rate of QFT-GIT results also decreased with increasing age (P < 0.001). As for disease types, the proportion of positive result in children with cardiovascular disease was significantly higher than that with other diseases (P < 0.001), and a higher proportion of indeterminate QFT-GIT result was observed among children with rheumatic disease (P < 0.001).

A comparison of indeterminate results for the two methods by age can be found in Fig. 3. The proportion of QFT-GIT indeterminate results was higher than that of X.DOT-TB across age groups.

Fig. 3
figure 3

Indeterminate X.DOT-TB and QFT-GIT TB results by Ages

Full size image

Risk factors for indeterminate results

Univariable logistic regression analysis revealed that indeterminate X.DOT-TB results differed across age groups. Using children aged between 15 and 17 as a control group, children under five years old were more likely to have indeterminate result (44.8%) than that with determinate result (33.1%). In addition, children, with digestive diseases (11.8%) and hematological and neoplastic diseases (14.6%), had significantly higher odds of having indeterminate result compared with determinate result (8.9% and 8.1%, respectively). Moreover, multivariate logistic modelling analysis showed that being male (adjusted odds ratio [aOR] 0.71, 95% CI 0.66–0.76), younger than 10 years (aOR 2.04, 95% CI 1.70–2.45 for children under 5 years old; aOR 1.37, 95% CI 1.14–1.64 for children 5–9 years of age), digestive diseases (aOR 1.61, 95% CI 1.43–1.82), hematological and neoplastic diseases (aOR 1.97, 95% CI 1.78–2.19) and rheumatic immune diseases (aOR 1.16, 95% CI 1.06–1.27) had a higher risk of indeterminate X.DOT-TB result (Table 3).

Table 3 Multivariate analysis of risk factors associated with Indeterminate X.DOT-TB results in childhood tuberculosis
Full size table

Univariable logistic regression analysis revealed that the rate of QFT-GIT indeterminate result for children under five years old (55.4%) was significantly higher than that of determinate result (29.2%). And the percentage of indeterminate result (32.1%) was significantly lower than that of determinate result (35.0%) for children aged 5 to 9. In addition, children with respiratory diseases (19.3%) and rheumatic immune diseases (27.3%) had significantly higher odds of having indeterminate result compared with determinate result (11.2% and 16.1%, respectively). Among the risk factors analyzed through logistic regression, gender, age and disease classification all presented a statistically significant association with an increased risk of obtaining indeterminate QFT-GIT results (Table 4).

Table 4 Multivariate analysis of risk factors associated with Indeterminate QFT-GIT results in childhood tuberculosis
Full size table

Discussion

Children living with HIV/AIDS, having a history of exposure to pulmonary TB cases, initiating anti-tumor necrosis factor therapy, receiving organ or hematologic transplantation, and patients with end-stage renal failure are at high risk of TB infection or progressingto active TB disease [7]. So screening for LTBI in this vulnerable population before treatment was necessary. In this study, we found that children under 5 years old with respiratory disease and hematological and neoplastic disease were more frequently to be screened for LTBI. Of which, pneumonia and anaemia was predominant, respectively. For children under 5 years old, acute lower respiratory tract infections predominating with pneumonia are the leading cause of death, which is difficult to distinguish from tuberculosis due to lack of typical clinical symptoms. Besides, physical and intellectual development is at a critical stage for children under 5 years old, but tuberculosis is often accompanied by malnutrition, which leads to anaemia [8]. For children between 5 and 17 years of age, henoch-schönlein purpura (HSP) of rheumatic immune disease was more likely to be screened for LTBI in our study. The immunosuppressive therapy of HSP, the most common form of systemic vasculitis in children, is a risk factor for reactivation of latent infections [9]. So these children were more likely to be screened for LTBI.

We found a positive rate of 3.1% for X.DOT-TB, and 1.8% for QFT-GIT. According to another research by our team, the positive rate of children younger than 18 years old was 5.3% and 2.2% for household contacts and non-household contacts, respectively [10]. The positive rate was 2.5% for participants aged 5–15 years old from a baseline survey in China for QFT-GIT [11]. Besides, consistent with previous studies [12, 13], significant difference in the positivity rate was observed across the age groups between X.DOT-TB and QFT-GIT in our study. The proportion of positive results in children between 10 and 14 years old (38.8% for X.DOT-TB, 42.5% for QFT) was significantly greater than that in other age groups. The reason may be that BCG vaccination protection declines with time, lasting about 10–15 years. Besides, developing immune system, heavy study load, nutritional imbalance, and lacking of physical exercise for children were on this age. Therefore, screening for LTBI before treatment was of important.

The indeterminate results complicated clinical management and increased costs of further diagnostic testing. In this study, male was more likely to have indeterminate results. However, the conclusions from different studies on gender were not consistent [14,15,16]. Younger age was considered to be associated with an indeterminate IGRA result [17,18,19]. Studies have shown that children aged <4 years old, frequency of indeterminate results was higher [20, 21]. Besides, earlier studies demonstrated that young age was independently associated with a higher risk of obtaining indeterminate QFT-GIT results [22, 23]. Consistent with previous studies, we found that both the indeterminate rate of X.DOT-TB and QFT-GIT decreased with increasing age. In addition, Kampmann et al. [24] found that IGRA responses were lower in children aged < 5 years than that aged 5 to 15 years. Some authors have proposed that very young children produce, on average, less IFN-γ than older children [25], which may explain the association. And from the multivariate analysis, our findings revealed that children younger than 10 years and children across all ages were considered a risk factor for the indeterminate X.DOT-TB and QFT-GIT results, respectively. However, the proportion of QFT-GIT indeterminate results was higher than that of X.DOT-TB results across age groups. We hypothesized that the lymphocyte adjustment in X.DOT-TB assays may reduce the risk of an indeterminate result, particularly in patients with reduced lymphocyte count, such as HIV infection or immunocompromising conditions associated with lymphopenia [3]. This assumption was confirmed by results from a meta-analysis, showing that low CD4 cell counts increased indeterminate rates of QFT-GIT but not of X.DOT-TB assays [26].

As for the disease classification, a higher proportion of indeterminate X.DOT-TB and QFT-GIT result was found among children with respiratory disease and rheumatic disease, respectively. Previous studies reported that low-dose steroids were used as adjuvant treatments for pneumonia, dyspnea in asthma, and acute respiratory distress syndrome [27]. Nevertheless, even low doses of steroids can significantly impact QFT-GIT results, with the highest OR for the indeterminate results [27]. Previous studies reported that an immunocompromised status contributed to indeterminate QFT-GIT results for children [23]. Besides, the immunosuppressive drugs treated for rheumatic disease can induce lymphopenia or impaired the function T-cells or antigen-presenting cells, which can significantly affect the indeterminate results [28]. In addition, some underlying diseases were found to be associated with the indeterminate IGRA results [29]. We found that digestive diseases, hematological and neoplastic diseases, and rheumatic immune diseases had a higher risk of indeterminate X.DOT-TB result, and diseases in this study all presented a statistically significant association with an increased risk of obtaining indeterminate QFT-GIT results. Given these risks, standard care was required when screening for LTBI in this vulnerable population.

The strength of this study lies in it was conducted in a routine clinical testing item rather than highly controlled conditions, which contributed to evaluate the test performance adequately. Besides, it involved a considerable number of children with various disease classification, contributing to elucidate the performance of IGRA in populations with certain risk factors. However, our study has some limitations. First, possible selection biases may have occurred due to the retrospective and single center sample of this study. Second, only partial clinical information was explored, which may lead to different results. Third, analysis on culture proven TB was not carried out. Finally, although several risk factors had been investigated, the contribution of other factors, such as HIV status, remained unclear and required further investigation.

Conclusions

In summary, the positive rates of X.DOT-TB and QFT-GIT in children were 3.1% and 1.8%, respectively. The X.DOT-TB assay performed better than QFT-GIT in children, and male, age and underlying diseases were associated with an increased risk of an indeterminate IGRA results.

Data Availability

Data supporting the results can be found in this paper. The datasets generated during and analyzed during the current study are available from the corresponding author on reasonable request.

Abbreviations

IGRA:

Interferon-gamma release assay

LTBI:

Latent TB infection

QFT-GIT:

QuantiFERON-TB Gold In-Tube

XDOT:

XDOT.TB

TB:

Tuberculosis

MTB:

Mycobacterium tuberculosis

ELISA:

Enzyme-linked Immunosorbent Assay

ELISPOT:

Enzyme-linked Immunospot Assay

PBMCs:

Peripheral blood mononuclear cells

SFCs:

Spot-forming cells

aOR:

Adjusted odds ratio

References

  1. World Health Organization. Global Tuberculosis Report 2022. Geneva, Switzerland: World Health Organization; 2022.

    Google Scholar 

  2. World Health Organization. Latent tuberculosis infection. Updated and consolidated guidelines for programmatic management. 2018.

  3. Meier NR, Volken T, Geiger M, Heininger U, Tebruegge M, Ritz N. Risk factors for Indeterminate Interferon-Gamma Release Assay for the diagnosis of Tuberculosis in Children-A systematic review and Meta-analysis. Front Pediatr. 2019;7:208.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Venturini E, Tersigni C, Chiappini E, de Martino M, Galli L. Optimizing the management of children with latent Tuberculosis Infection. Expert Rev Anti Infect Ther. 2017;15(4):341–9.

    Article  CAS  PubMed  Google Scholar 

  5. Starke JR, Committee On Infectious D. Interferon-gamma release assays for diagnosis of Tuberculosis Infection and Disease in children. Pediatrics. 2014;134(6):e1763–73.

    Article  PubMed  Google Scholar 

  6. Pai M, Behr M. Latent Mycobacterium tuberculosis Infection and Interferon-Gamma release assays. Microbiol Spectr. 2016;4(5).

  7. World Health Organization. Guidelines on the management of latent Tuberculosis Infection. Geneva, Switzerland: WHO; 2014.

    Google Scholar 

  8. Du Y, Liao Y, Leng F et al. Anaemia prevalence and its associated factors in children under 5 years in Western China: a systematic review. BMJ Paediatr Open. 2022;6(1).

  9. Mizerska-Wasiak M, Winiarska M, Nogal K, Cichon-Kawa K, Panczyk-Tomaszewska M, Maldyk J. IgA Vasculitis complicated by both CMV reactivation and Tuberculosis. Pediatr Rep. 2021;13(3):416–20.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Sun L, Qi X, Guo Y, et al. Tuberculosis Infection screening in children with close contact: a hospital-based study. BMC Infect Dis. 2021;21(1):815.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Li H, Xin H, Qian S, et al. Testing of Tuberculosis Infection among Chinese adolescents born after terminating the Bacillus Calmette-Guerin booster vaccination: subgroup analysis of a population-based cross-sectional study. Front Med. 2017;11(4):528–35.

    Article  PubMed  Google Scholar 

  12. Mahomed H, Hawkridge T, Verver S, et al. Predictive factors for latent Tuberculosis Infection among adolescents in a high-burden area in South Africa. Int J Tuberc Lung Dis. 2011;15(3):331–6.

    CAS  PubMed  Google Scholar 

  13. Connell TG, Ritz N, Paxton GA, Buttery JP, Curtis N, Ranganathan SC. A three-way comparison of tuberculin skin testing, QuantiFERON-TB gold and X.DOT-TB in children. PLoS ONE. 2008;3(7):e2624.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Kobashi Y, Sugiu T, Mouri K, Obase Y, Miyashita N, Oka M. Indeterminate results of QuantiFERON TB-2G test performed in routine clinical practice. Eur Respir J. 2009;33(4):812–5.

    Article  CAS  PubMed  Google Scholar 

  15. Oni T, Gideon HP, Bangani N, et al. Risk factors associated with indeterminate gamma interferon responses in the assessment of latent Tuberculosis Infection in a high-incidence environment. Clin Vaccine Immunol. 2012;19(8):1243–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Beffa P, Zellweger A, Janssens JP, Wrighton-Smith P, Zellweger JP. Indeterminate test results of X.DOT-TB performed under routine field conditions. Eur Respir J. 2008;31(4):842–6.

    Article  CAS  PubMed  Google Scholar 

  17. Banfield S, Pascoe E, Thambiran A, Siafarikas A, Burgner D. Factors associated with the performance of a blood-based interferon-gamma release assay in diagnosing Tuberculosis. PLoS ONE. 2012;7(6):e38556.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Critselis E, Amanatidou V, Syridou G, et al. The effect of age on whole blood interferon-gamma release assay response among children investigated for latent Tuberculosis Infection. J Pediatr. 2012;161(4):632–8.

    Article  CAS  PubMed  Google Scholar 

  19. Jenum S, Selvam S, Mahelai D, et al. Influence of age and nutritional status on the performance of the tuberculin skin test and QuantiFERON-TB gold in-tube in young children evaluated for Tuberculosis in Southern India. Pediatr Infect Dis. 2014;33(10):e260–9.

    Article  Google Scholar 

  20. Li T, Bao L, Diao N, et al. Influencial factors of the performance of interferon-gamma release assays in the diagnosis of childhood Tuberculosis. Clin Exp Med. 2015;15(3):303–9.

    Article  CAS  PubMed  Google Scholar 

  21. Bergamini BM, Losi M, Vaienti F, et al. Performance of commercial blood tests for the diagnosis of latent Tuberculosis Infection in children and adolescents. Pediatrics. 2009;123(3):e419–24.

    Article  PubMed  Google Scholar 

  22. Connell TG, Tebruegge M, Ritz N, Bryant PA, Leslie D, Curtis N. Indeterminate interferon-gamma release assay results in children. Pediatr Infect Dis J. 2010;29(3):285–6.

    Article  PubMed  Google Scholar 

  23. Haustein T, Ridout DA, Hartley JC, et al. The likelihood of an indeterminate test result from a whole-blood interferon-gamma release assay for the diagnosis of Mycobacterium tuberculosis Infection in children correlates with age and immune status. Pediatr Infect Dis. 2009;28(8):669–73.

    Article  Google Scholar 

  24. Kampmann B, Tena-Coki G, Anderson S. Blood tests for diagnosis of Tuberculosis. Lancet. 2006;368(9532):282. author reply 282-3.

    Article  PubMed  Google Scholar 

  25. Connell TG, Curtis N, Ranganathan SC, Buttery JP. Performance of a whole blood interferon gamma assay for detecting latent Infection with Mycobacterium tuberculosis in children. Thorax. 2006;61(7):616–20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Cattamanchi A, Smith R, Steingart KR, et al. Interferon-gamma release assays for the diagnosis of latent Tuberculosis Infection in HIV-infected individuals: a systematic review and meta-analysis. J Acquir Immune Defic Syndr. 2011;56(3):230–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Kim KH, Kang JM, Ahn JG. Low-dose steroids are associated with indeterminate QuantiFERON-TB gold In-Tube assay results in immunocompetent children. Sci Rep. 2021;11(1):6468.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Helwig U, Muller M, Hedderich J, Schreiber S. Corticosteroids and immunosuppressive therapy influence the result of QuantiFERON TB gold testing in inflammatory bowel Disease patients. J Crohns Colitis. 2012;6(4):419–24.

    Article  PubMed  Google Scholar 

  29. Wang MS, Liu XJ. Risk factors for false-negative Interferon-gamma release assay results in culture-confirmed childhood TB. Am J Trop Med Hyg. 2019;101(6):1303–7.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

We thank the staff members of the Laboratory of Respiratory Diseases, affiliated with the Beijing Pediatric Research Institute.

Funding

This work was supported by Beijing Natural Science Foundation (7224328, 7202043), high-level public health technical personnel construction project training plan (subject backbone-02-33), and Beijing science and technology nova cross project (20230484439).

Author information

Authors and Affiliations

  1. Laboratory of Respiratory Diseases, Beijing Key Laboratory of Pediatric Respiratory Infection Diseases, Beijing Children’s Hospital, Key Laboratory of Major Diseases in Children, Ministry of Education, National Clinical Research Center for Respiratory Diseases, Beijing Pediatric Research Institute, Capital Medical University, National Center for Children’s Health, Beijing, 100045, China

    Huiwen Zheng, Jing Xiao, Feina Li, Hao Chen, Yonghong Wang, Yajie Guo, Yuying Chen & Chen Shen

  2. Department of Respiratory Medicine, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing, China

    Deze Li

Authors
  1. Huiwen Zheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jing Xiao
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Feina Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hao Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Deze Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yonghong Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yajie Guo
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Yuying Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Chen Shen
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

LFN, CH, and LDZ contributed in study design, data collection, and analysis. ZHW and XJ conducted in manuscript writing. WYH, GYJ, and CYY conducted laboratory testing; SC revised the manuscript. All the authors have read the manuscript and have approved it.

Corresponding author

Correspondence to Chen Shen.

Ethics declarations

Ethics approval and consent to participate

This study was approved by the Ethics Committee of Beijing Children’s Hospital. All methods were carried out in accordance with relevant guidelines and regulations. Confirming informed consent was obtained from all the participants in the study. For participants under 16 years of age, confirming informed consent was obtained from the legal guardian of these participants.

Consent for publication

Not Applicable.

Conflict of interest

No conflict of interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary Material 1:

The result criteria for QFT-GIT and X.DOT-TB

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zheng, H., Xiao, J., Li, F. et al. Interferon-gamma release assay for screening of tuberculosis infection in children. BMC Infect Dis 23, 873 (2023). https://doi.org/10.1186/s12879-023-08871-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12879-023-08871-z

Keywords

BMC Infectious Diseases

ISSN: 1471-2334

Contact us